Mipomersen sodium

• CAT Number: I032325
• CAS Number: 629167-92-6
• Molecular Weight: 7595.00
• Purity: ≥95%

Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH)[1][2].
Mipomersen predominantly distributes to the liver and decreases the production of apoB-100, the primary structural protein of the atherogenic lipoproteins including low density lipoprotein (LDL), thereby reducing plasma LDL-cholesterol and apoB-100 concentrations[2].
Apolipoprotein (apo) B, a large amphipathic protein, plays a fundamental role in human lipoprotein metabolism. ApoB-100 is also a ligand for LDL receptor-mediated endocytosis of LDL by cells[2].

Reference

[1]. Philip Hair, et al. Mipomersen sodium: first global approval. Drugs. 2013 Apr;73(5):487-93.
 [Content Brief]

[2]. Damon A Bell, et al. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin Investig Drugs. 2011 Feb;20(2):265-72.
 [Content Brief]